Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Rigel R&D Strategy Emphasizes Early Pipeline, Led By Asthma Drug

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Rigel’s focus on its early-stage projects for serious unmet medical needs overshadowed its Phase III rheumatoid arthritis candidate with AstraZeneca.

Advertisement

Related Content

With Much Riding On Fostamatinib, Rigel Awaits The Phase III Results
Roche Believes Biomarker Could Position Antibody For Severe Asthma For Success
Tofacitinib Data Is In: As Effective As Humira, But Safety Remains A Question

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS004867

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel